Invesco
CYCN icon

Invesco’s Cyclerion Therapeutics CYCN Stock Holding History

Invesco’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,729
Closed -$106K – 3874
2020
Q4 		$106K Buy
1,729
+78
+5% +$5.32K ﹤0.01% 3633
2020
Q3 		$201K Sell
1,651
-49
-3% -$5.6K ﹤0.01% 3455
2020
Q2 		$201K Sell
1,700
-195
-10% -$16.3K ﹤0.01% 3472
2020
Q1 		$100K Buy
+1,895
New +$135K ﹤0.01% 3568

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Invesco's CYCN Position: Q1 2021 in Review

Invesco sold out of Cyclerion Therapeutics (CYCN) in Q1 2021, closing a stake of 1,729 shares — an estimated $106K sold.

Invesco first reported a position in CYCN in Q1 2020 and held it in 4 quarters. The position peaked at $201K in Q3 2020. 70 funds tracked by Wall St. Rank hold CYCN as of Q1 2021.

  • Invesco reported no remaining Cyclerion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Invesco sold 1,729 Cyclerion Therapeutics shares in Q1 2021, an estimated $106K.
  • Invesco first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 4 quarters.
  • Invesco's Cyclerion Therapeutics position peaked at $201K in Q3 2020.
  • 70 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2021.

Based on Invesco's 13F filing for Q1 2021, filed 17 May 2021.